The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
Abrocitinib 100mg and 200mg met both co-primary end points achieving superiority to placebo at Weeks 12 and 16.
The FDA has granted Breakthrough Therapy designation to baricitinib (LY3009104; Lilly), an oral Janus Kinase (JAK) inhibitor, for the treatment of alopecia areata.
The FDA has accepted for filing the New Drug Application for tirbanibulin ointment (formerly known as KX2-391 or KX-01 ointment; Athenex) for the treatment of actinic keratosis (AK).
Results showed that patients with mild atopic dermatitis did see significant improvement in pruritus.
RedDress announced the launch of ActiGraft as the first wound care treatment that enables healthcare providers to produce – in real time – a patient’s blood into an autologous whole blood clot tissue to heal wounds and ulcers.
Incyte announced positive topline results from the TRuE-AD clinical trial program (TRuE-AD1 and TRuE-AD2) of ruxolitinib cream for the treatment of atopic dermatitis in patients aged 12 years and older.
Positive topline data were announced from the pivotal phase 3 TRuE-AD2 study of ruxolitinib cream for the treatment of atopic dermatitis in patients aged ≥12 years.
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
Results showed that the 4mg dose of baricitinib plus TCS met the primary end point, with 31.5% of patients achieving EASI75 compared with 17.2% of patients in the placebo plus TCS group (P ≤.05).
